The prevalence of diabetes in India more than doubled in the 16 years since 2005. The number of cases increased from 42.6 mn in 2005 to 85.4 mn in 2019 as per the latest available data. The disease incidence, which increases rapidly in individuals above 35 years, rose at a rate of around 3 million cases per year on average.
Findings of a National Level Survey conducted by The Associated Chambers of Commerce and Industry of India (ASSOCHAM) on the state of diabetes in India revealed that the disease currently accounts for 12.8 million DALYs (Disability-Adjusted Life Years), 6.7 million YLDs (Years Lived with Disability) and 0.3 million deaths during 20052019.
Globally, on the other hand, the prevalence of diabetes increased from 273.4 cases in 2005 to 460 million cases in 2019. Small wonder then that India has the dubious distinction of becoming the global hub for diabetes cases with prevalence increasing from 15.6 percent to 18.6 percent cases in the same interval. Globally, diabetes accounts for 70.9 million DALYs (Disability-Adjusted Life Years) and 36.7 YLDs (Years Lived with Disability) in 2019.
Similar results were found in another prevalence survey conducted by a team of researchers from Vivekananda Yoga Anusandhana Samsthana, Bengaluru, Department of Biophysics, Postgraduate Institute of Medical Education and Research, Chandigarh, Neuroscience Research Lab at Postgraduate Institute of Medical Education and Research, Chandigarh, College of Social Work at University of Kentucky, US, and Government Medical College and Hospital, Chandigarh, reported in December, 2020. The survey found that India has a high, medium and low diabetes risk score (IDRS) of 10.2 percent, 33.1 percent and 56.7 percent in young adults. The IDRS considers four key factors, including age, family history of diabetes, waist circumference and physical activity.
ãã®èšäºã¯ Future Medicine India ã® December 2021 çã«æ²èŒãããŠããŸãã
7 æ¥éã® Magzter GOLD ç¡æãã©ã€ã¢ã«ãéå§ããŠãäœåãã®å³éžããããã¬ãã¢ã ã¹ããŒãªãŒã8,500 以äžã®éèªãæ°èã«ã¢ã¯ã»ã¹ããŠãã ããã
ãã§ã«è³Œèªè ã§ã ?  ãµã€ã³ã€ã³
ãã®èšäºã¯ Future Medicine India ã® December 2021 çã«æ²èŒãããŠããŸãã
7 æ¥éã® Magzter GOLD ç¡æãã©ã€ã¢ã«ãéå§ããŠãäœåãã®å³éžããããã¬ãã¢ã ã¹ããŒãªãŒã8,500 以äžã®éèªãæ°èã«ã¢ã¯ã»ã¹ããŠãã ããã
ãã§ã«è³Œèªè ã§ã? ãµã€ã³ã€ã³
Early Reports On Omicron Encouraging: Anthony Fauci
Even as the Omicron variant of coronavirus is spreading across the world quickly, early reports suggest that it may cause less severe disease than the Delta variant, says Anthony Fauci, MD, director of the National Institute of Allergy and Infectious Diseases, US.
Air Pollution Reduces 8 Years Of Life Expectancy In India
India registers 18 percent of deaths annually due to air pollution and related diseases, while nationwide socioeconomic inequalities persist in asthma diagnosis across India
Importance Of Adhering To Covid Appropriate Behaviour
As the efficacy of existing vaccines has been proven to be inadequate against Omicron, our only hope from the jab is to reduce the severity of the disease, highlighting the importance of adhering to covid appropriate behaviour
AstraZeneca's new covid drug AZD7442 shows 83% prevention and 88% treatment efficacy
AstraZeneca, which announced the latest data from Phase III trials of its new Covid-19 drug -- AZD7442 -- said both the prevention and outpatient treatment studies showed robust efficacy from a onetime intramuscular (IM) dose of the long-acting antibody combination.
VACCINES IN YOUR POCKET
DR. SAUMYA SWAMINATHAN Cheif Scientist, World Health Organisation
DIABETES, AT CLOSE TO 91 MILLION CASES, ACCOUNTS FOR 25% OF ALL NCDS IN INDIA
The disease incidence, which increases very rapidly in individuals above 35 years of age, accounts for 12.8 million DALYs, 6.7 million YLDs
EXPERTS PREDICT THIRD WAVE IN INDIA WITH MORE THAN A LAKH DAILY CASES IN FEBRUARY
The active cases have come down as compared July leveld, the threat of new variants is looming large.
END INEQUALITIES TO MEET THE TARGET OF ENDING AIDS
Forty years after the first AIDS case was reported, and 35 years since the first case in India, HIV still threatens us. Today, the world is off track from delivering on the shared commitment to end AIDS by 2030.
CONVENTIONAL LINEN IS ONE OF THE BIGGEST CULPRITS IN HOSPITAL ACQUIRED AS WELL AS SURGICAL SITE INFECTIONS
The âgreen colourâ linen is synonymous with hospitals, as it has been in use for centuries in hospitals world over, especially the conventional healthcare settings. But how many, even in the medical community, are really conscious about the responsibility for and the critical role of this piece of medical accessory in ensuring patient safety? Evidence from most hospitals in India indicates that not many are aware of the standards, and even if they are, not many bother with them. Again, going by real world experience, there exists another paradox. Though the actual cost of the repeated use of the linen is higher than the cost of single-use disposables (recommended in modernday care), it is still being used in a large majority of hospitals and clinics in India â because it is the convention. Therefore, transformation hesitance is more of a mindset issue rather than ignorance or economics. Most in the industry also oppose quality regulations in the country. In a market where hundreds of textile weavers and cloth merchants turned medical mask and accessory manufacturers overnight during the Covid pandemic, the market situation serves the unscrupulous minds who only eye the profits. However, there are a handful of local companies, besides the large organised players, who stick to quality products in this predominently price conscious market due to internal SOPs or pure commitment. For JAMES GEORGE, Founder and Managing Director at Kochi-based Careon Healthcare Solutions, it is more of a personal commitment. In a freewheeling interview with Editor CH UNNIKRISHNAN, George says that the primary reason behind the rise of unscrupulous players in the medical disposables market is lack of awareness among the users and the patients. Edited excerpts:
UK approves sotrovimab as new covid treatment for high risk adults
The Medicines and Healthcare Products Regulatory Agency (MHRA), the drug regulator of the UK, has approved sotrovimab, branded as Xevudy, a new biological drug to fight Covid-19. The drug was found effective to reduce the likelihood of hospital admission and death by about 79 percent in high-risk adults.
